Encouraging safety and efficacy data on novel and emerging therapies signal an important step forward in the development of treatment strategies for patients with hard-to-treat leukemia, myeloma, and myelofibrosis.
Encouraging safety and efficacy data on novel and emerging therapies signal an important step forward in the development of treatment strategies for patients with hard-to-treat leukemia, myeloma, and myelofibrosis.